Stellar Biotechnologies, Inc. (“Stellar” or “the Company”) (NASDAQ: SBOT) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (“KLH”), will welcome two Mexican government officials to their headquarters in Port Hueneme on November 10. The visit follows Stellar Biotechnologies commencing trade on the NASDAQ, yesterday.
The officials are coming together in support of Stellar’s efforts to promote sustainable aquaculture, while contributing to the development of vital proteins for human immunotherapies. This meeting is building upon the recent California State Senate letter of intent with the Mexican government, encouraging California business leaders to make connections between California and Mexico. It also comes in the wake of the United Nation announcing their Global Goals for Sustainable Development, including ocean resources.
Government officials and Stellar Management will be available for in-person and phone interviews during the event. Please RSVP to email@example.com if you are able to attend or would like to schedule a phone interview.
Please see details about the event below:
WHERE: Port Hueneme, CA
WHEN: Tues., Nov. 10; 6 p.m.— 9 p.m. PT
WHAT: Stellar Biotechnologies is welcoming two Mexican officials to their facility in Port Hueneme. The two have supported Stellar’s expansion to the second site in Baja due to Stellar’s commitment to sustainable aquaculture. This visit to the completed facility is an effort to continue the positive relationship between the Company and the officials.
WHO: Matias Arjona Rydalch, the Secretary of Fisheries and Aquaculture,
Louis Andres Gonzalez Agraz, Director of Aquaculture.
Frank Oakes, CEO of Stellar Biotechnologies
More About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (OTCQB: SBOTD) (TSX Venture: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer’s and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.